About: Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review
Creator	Bielicki, Julia Fuchs, Aline Mathur, Shrey Sharland, Mike Van Den Anker, Johannes
Source	Medline; PMC
abstract	Background Pneumonia is the most common cause of death in children worldwide, accounting for 15% of all deaths of children under 5 years of age. This review summarises the evidence for the empirical antibiotic treatment of community-acquired pneumonia in neonates and children and puts emphasis on publications since the release of the previous WHO Evidence Summary report published in 2014. Methods A systematic search for systematic reviews and meta-analyses of antibiotic therapy for community-acquired pneumonia was conducted between 1 January 2013 and 10 November 2016. Results The optimal dosing recommendation for amoxicillin remains unclear with limited pharmacological and clinical evidence. There is limited evidence from surveillance to indicate whether amoxicillin or broader spectrum antibiotics (e.g. third-generation cephalosporins) are being used most commonly for paediatric CAP in different WHO regions. Data are lacking on clinical efficacy in the context of pneumococcal, staphylococcal and mycoplasma disease and the relative contributions of varying first-line and step-down options to the selection of such resistance. Conclusion Further pragmatic trials are required to optimise management of hospitalised children with severe and very severe pneumonia.
has issue date	2018-05-23(xsd:dateTime)
bibo:doi	10.1080/20469047.2017.1409455
bibo:pmid	29790844
has license	cc-by
sha1sum (hex)	348e9d5eb25a7d8b2b9597d7a24642eb67abc034
schema:url	https://doi.org/10.1080/20469047.2017.1409455
resource representing a document's title	Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review
has PubMed Central identifier	PMC6176769
has PubMed identifier	29790844
schema:publication	Paediatr Int Child Health
resource representing a document's body	covid:348e9d5eb25a7d8b2b9597d7a24642eb67abc034#body_text
is schema:about of	named entity 'systematic reviews' named entity 'accounting' named entity 'Results' named entity 'SEVERE PNEUMONIA' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'PHARMACOLOGICAL' named entity 'VARYING' named entity 'EVIDENCE' named entity 'CHILDREN' named entity 'LIMITED' named entity 'THIRD-GENERATION CEPHALOSPORINS' named entity 'RECOMMENDATION' named entity 'CHILDREN' named entity 'CONCLUSION' named entity 'DATA' named entity 'EMPIRICAL' named entity 'CAP' named entity 'UNCLEAR' named entity 'NEONATES' named entity 'RESISTANCE' named entity 'SPECTRUM' named entity 'PNEUMONIA' named entity 'TO INDICATE' named entity 'PUBLICATIONS' named entity 'USED' named entity 'LACKING' named entity 'CAUSE OF DEATH' named entity 'MANAGEMENT' named entity 'SELECTION' named entity 'COMMON' named entity 'ANTIBIOTIC THERAPY' named entity 'AGE' named entity 'ACCOUNTING' named entity 'YEARS' named entity 'VERY SEVERE' named entity 'COMMUNITY-ACQUIRED PNEUMONIA' named entity 'JANUARY' named entity 'BEING' named entity 'OPTIONS' named entity 'EVIDENCE FOR' named entity 'ANTIBIOTICS' named entity 'PUBLISHED' named entity 'STAPHYLOCOCCAL' named entity 'NOVEMBER' named entity 'PNEUMOCOCCAL' named entity 'SYSTEMATIC REVIEWS' named entity 'PREVIOUS' named entity 'STEP' named entity 'RELATIVE' named entity 'PAEDIATRIC' named entity 'DISEASE' named entity 'CONTEXT' named entity 'EVIDENCE' named entity 'AMOXICILLIN' named entity 'OPTIMAL' named entity 'SUMMARY REPORT' named entity 'DOSING' named entity 'PRAGMATIC TRIALS' named entity 'LINE' named entity 'BACKGROUND' named entity 'REQUIRED' named entity 'RELEASE' named entity 'RESULTS' named entity 'REVIEW' named entity 'MYCOPLASMA' named entity 'CLINICAL EFFICACY' named entity 'ANTIBIOTIC USE' named entity 'DIFFERENT' named entity 'SEVERE' named entity 'METHODS' named entity 'SEARCH' named entity 'CLINICAL' named entity 'WORLDWIDE' named entity 'META-ANALYSES' named entity 'NEONATES' named entity 'REVIEW' named entity 'REGIONS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software